With more than two decades of regulatory and clinical development experience in the Pharma, Biotech and Medical Device fields, Deepak Chadha is responsible for leading Brickell’s R&D organization.
Mr. Chadha's management experience encompasses providing strategic vision, leadership, and oversight to ensure the successful execution of global product development programs, including direct responsibility over the preclinical, CMC, quality, clinical and regulatory functions. Mr. Chadha has worked on various product development projects for drugs, biologics, medical devices and combination products, including marketing applications to the FDA, the EMA, as well as the regulatory agencies of the UK, Canada, Australia, and Japan among others, which resulted in the approval of several products that went on to become best-in-class within their respective areas.
Prior to Brickell, Mr. Chadha held the role of Vice President, Global Regulatory Affairs at Suneva Medical. During his time at Suneva Medical, Mr. Chadha led the regulatory approval for BELLAFILL® dermal filler for acne scar correction and supported the company’s commercial products life cycle management. Before Suneva, Mr. Chadha worked at Allergan (f.k.a. KYTHERA), where Mr. Chadha successfully led their lead product, KYBELLA®, from an early clinical phase to an NDA stage, and also supported the ex-US regulatory activities. Mr. Chadha also served as Vice President of Global Regulatory Affairs at Allergan Medical (f.k.a. Inamed Corporation), where he assisted in building the organization’s Global Regulatory Affairs department, and was involved with the approval for JUVEDERM®, Bioenterics®, LAP-BAND® and Silicone gel-filled Breast Implants. In addition, his career has included positions of increasing responsibility at Biomeasure Inc. (IPSEN) and Stryker Biotech.
Mr. Chadha holds a BS in Pharmaceutical Sciences from Berhampur University in Orissa, India, an MS in Pharmaceutics from Hamdard University in New Delhi, India, and an MBA in International Business from California State University, Dominguez Hills.
What is Deepak Chadha's net worth?
The estimated net worth of Deepak Chadha is at least $0.00 as of May 18th, 2021. Mr. Chadha owns 65,667 shares of Brickell Biotech stock worth more than $0 as of April 20th. This net worth estimate does not reflect any other assets that Mr. Chadha may own. Additionally, Mr. Chadha receives an annual salary of $543,590.00 as Insider at Brickell Biotech. Learn More about Deepak Chadha's net worth.
How old is Deepak Chadha?
Mr. Chadha is currently 52 years old. There are 6 older executives and no younger executives at Brickell Biotech. The oldest executive at Brickell Biotech is Mr. Albert Nicholas Marchio II, CFO and Principal Accounting & Financial Officer, who is 70 years old. Learn More on Deepak Chadha's age.
What is Deepak Chadha's salary?
As the Insider of Brickell Biotech, Inc., Mr. Chadha earns $543,590.00 per year. There are 2 executives that earn more than Mr. Chadha. The highest earning executive at Brickell Biotech is Attorney Robert Busard Brown, CEO & Director, who commands a salary of $816,730.00 per year. Learn More on Deepak Chadha's salary.
How do I contact Deepak Chadha?
Has Deepak Chadha been buying or selling shares of Brickell Biotech?
Deepak Chadha has not been actively trading shares of Brickell Biotech during the last ninety days. Most recently, on Tuesday, May 18th, Deepak Chadha bought 2,700 shares of Brickell Biotech stock. The stock was acquired at an average cost of $0.82 per share, with a total value of $2,214.00. Following the completion of the transaction, the insider now directly owns 65,667 shares of the company's stock, valued at $53,846.94. Learn More on Deepak Chadha's trading history.
Who are Brickell Biotech's active insiders?
